Company: GMRE
Filing Date: 2025-11-18
Form Type: 8-K
Source: 0001104659-25-113664
Chunk: 0

Company: Global Medical REIT Inc.
Filing Date: 2025-11-18
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

Underwriting Agreement

On November 13, 2025, Global Medical REIT Inc.
(the “ Company”) and Global Medical REIT L. P., the Company’s operating partnership (the “ Operating Partnership”),
entered into an Underwriting Agreement (the “ Underwriting Agreement”) with Raymond James & Associates, Inc., BMO Capital
Markets Corp., Stifel, Nicolaus & Company, Incorporated and Robert W. Baird & Co. Incorporated, as the representatives of the
underwriters named in Schedule A thereto (the “ Underwriters”), for the issuance and sale of 2,000,000 shares of its 8.00%
Series B cumulative redeemable preferred stock, par value $0.001 per share (the “ Series B Preferred Stock”), at a public offering
price of $25.00 per share (the “ Offering”). Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters
a 30-day option to purchase up to an additional 300,000 shares of Series B Preferred Stock at the public offering price per share to cover
over-allotments, if any.

The Offering is expected to close on November
20, 2025, subject to customary closing conditions. The Underwriting Agreement contains certain customary representations, warranties and
agreements by the Company and the Operating Partnership, conditions to closing, indemnification rights and obligations of the parties
and termination provisions. The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K, and the description
of the material terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit.

A copy of the opinion of Venable LLP, Maryland
counsel to the Company, relating to the legality of the shares of Series B Preferred Stock is filed as Exhibit 5.1 hereto.

First Amendment to Agreement of Limited
Partnership of the Operating Partnership

In connection with the
Offering, the Agreement of Limited Partnership of the Operating Partnership was amended to provide for the issuance of up to 2,300,000
of the Operating Partnership’s 8.00% Series B Cumulative Redeemable Preferred Units (liquidation preference $25.00 per unit) (the
“ Series B Preferred Units”). Such amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by
reference herein. The Company